Literature DB >> 15752405

Vasodilatory shock in severe acute pancreatitis without sepsis: is there any place for hydrocortisone treatment?

A Eklund1, A Leppäniemi, E Kemppainen, V Pettilä.   

Abstract

BACKGROUND: Hydrocortisone (HC) has been reported to rapidly improve hemodynamics and reduce the time to vasopressor cessation in septic shock, but none has focused on this effect in acute pancreatitis. We therefore performed a study to assess the effects of hydrocortisone on catecholamine-dependent shock among patients with severe acute pancreatitis.
METHODS: A retrospective, case-controlled study among 10 patients with severe acute pancreatitis and HC treatment for catecholamine-dependent shock was performed. The control group comprised 11 conventionally treated patients with the same severity of pancreatitis and circulatory shock according to the norepinephrine support required. In focus were the first 48 h from the start of HC administration in the HC group and from the reference point in the control group, respectively. The reference point for the control group was the time point at which doses of norepinephrine exceeded 0.3 microg kg(-1) min(-1).
RESULTS: Patients in the HC group were weaned off norepinephrine in a significantly shorter time (61 h in HC group vs. 141 h, P = 0.016). The HC group received significantly less norepinephrine (area under curve of norepinephrine dose, P = 0.041). The reduction in norepinephrine dose was comparable at 24 h, being -0.051 (-0.208-0.022) microg kg(-1) min(-1) in the HC group vs. -0.026 (-0.150-0.030) microg kg(-1) min(-1) in the controls (P = 0.307), and at 48 h with respective figures of -0.206 (-0.317 to -0.102) microg kg(-1) min(-1) and -0.103 (-0.178-0.029) microg kg(-1) min(-1) (P = 0.072), from the start of HC administration.
CONCLUSION: According to our data it seems reasonable to formulate a hypothesis that low doses of HC shorten the time to vasopressor cessation and rapidly reduce the need for norepinephrine support in patients with shock associated with severe acute pancreatitis without sepsis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15752405     DOI: 10.1111/j.1399-6576.2004.00585.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  6 in total

1.  Influence of hydrocortisone, prednisolone, and NO association on the evolution of acute pancreatitis.

Authors:  Laura Iris Cosen-Binker; Marcelo Gustavo Binker; Rodica Cosen; Gustavo Negri; Osvaldo Tiscornia
Journal:  Dig Dis Sci       Date:  2006-05-03       Impact factor: 3.199

2.  Relative adrenal insufficiency in patients with severe acute pancreatitis.

Authors:  Jan J De Waele; Eric A J Hoste; Didier Baert; Koen Hendrickx; Dirk Rijckaert; Patrick Thibo; Philippe Van Biervliet; Stijn I Blot; Francis Colardyn
Journal:  Intensive Care Med       Date:  2007-06-16       Impact factor: 17.440

Review 3.  Definitions and pathophysiology of vasoplegic shock.

Authors:  Simon Lambden; Ben C Creagh-Brown; Julie Hunt; Charlotte Summers; Lui G Forni
Journal:  Crit Care       Date:  2018-07-06       Impact factor: 9.097

4.  Critical illness-related corticosteroid insufficiency in patients with severe acute biliary pancreatitis: a prospective cohort study.

Authors:  Yun-Shing Peng; Cheng-Shyong Wu; Yung-Chang Chen; Jau-Min Lien; Ya-Chung Tian; Ji-Tseng Fang; Chun Yang; Yun-Yi Chu; Chien-Fu Hung; Chih-Wei Yang; Pang-Chi Chen; Ming-Hung Tsai
Journal:  Crit Care       Date:  2009-07-24       Impact factor: 9.097

Review 5.  Corticosteroid treatment for acute/acute-on-chronic experimental and naturally occurring pancreatitis in several species: a scoping review to inform possible use in dogs.

Authors:  Kari-Anne Bjørnkjær-Nielsen; Charlotte Reinhard Bjørnvad
Journal:  Acta Vet Scand       Date:  2021-07-13       Impact factor: 1.695

6.  The adrenocorticotropic hormone-induced cortisol response in acute pancreatitis.

Authors:  A B Johan Groeneveld
Journal:  Crit Care       Date:  2009-09-16       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.